Mesoblast (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry.
Melbourne-based Mesoblast is a biopharma company specialising in cell therapies. It has used its proprietary technology platform to establish a clinically advanced and diverse portfolio of cell-based product candidates. It currently has three cell therapy product candidates in Phase 3 clinical trials, in acute Graft versus Host Disease, chronic heart failure, and chronic lower back pain caused by disc degeneration. The Company expects to report primary endpoint results from its Phase 3 trial in paediatric acute Graft versus Host Disease in for first quarter 2018.
Frost & Sullivan analyst and industry manager, transformational health, Sanjeev Kumar, said, "Mesoblast is an international industry leader due to its cutting edge mesenchymal lineage cell technology platform, deep intellectual property portfolio, late-phase clinical assets, and industrialized manufacturing capabilities."
Mesoblast chief executive, Silviu Itescu, welcomed the award.
“We are honoured to be the first company named by Frost & Sullivan as the Global Technology Leader in the Cell Therapy Industry. This award recognizes the efforts of the whole Mesoblast team and our investors whose support has been instrumental in the development of our innovative cell therapy product candidates,” he said
Frost & Sullivan’s Best Practices Awards recognise companies that lead the development and successful introduction of high-tech solutions to customers’ most pressing needs, altering the industry or business landscape in the process. Its industry analyst team benchmarks market participants and measures their performance through independent, primary interviews, and secondary industry research to evaluate and identify best practices.